The use of genetic tests and genetic information by life insurance companies: does this differ from the use of routine medical information?
Questions regarding insurance companies' access to and use of genetic test results and genetic information have been raised since the advent of the Human Genome Project. The ability to place applicants of similar risks in groups, a process known as underwriting, is critical to the availability and affordability of individually underwritten life, disability income, and long-term care insurance. This paper focuses on how life insurance companies use medical information and particularly genetic test results and other genetic information in the risk assessment process. Issues and concerns raised about differences between routine medical information and genetic information are addressed and policies with regard to privacy and confidentiality are presented.
Zimmerman
S E
SE
American Council of Life Insurance, Washington, DC 20004, USA.
D003219:Confidentiality / Q000331:legislation & jurisprudence*; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000331:legislation & jurisprudence*; D017408:Guidelines as Topic; D006801:Humans; D007341:Insurance / Q000331:legislation & jurisprudence / Q000592:standards*; D008499:Medical Records / Q000331:legislation & jurisprudence*; D014342:Truth Disclosure; D014481:United States